Skip to content

Advertisement

BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β-catenin/EMT signaling cascade in gastric cancer

  • Jin Huang1,
  • Yijing He2,
  • Howard L. Mcleod3, 4, 5,
  • Yanchun Xie1,
  • Desheng Xiao6,
  • Huabin Hu7,
  • Pan Chen8,
  • Liangfang Shen1,
  • Shan Zeng1,
  • Xianli Yin9,
  • Jie Ge10,
  • Li Li1,
  • Lanhua Tang1,
  • Jian Ma11Email author and
  • Zihua Chen10Email author
Contributed equally
BMC Cancer201717:886

https://doi.org/10.1186/s12885-017-3875-3

Received: 3 May 2017

Accepted: 4 December 2017

Published: 22 December 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
3 May 2017 Submitted Original manuscript
6 Aug 2017 Reviewed Reviewer Report - Kwang-Huei Lin
14 Aug 2017 Reviewed Reviewer Report - Aditi Chatterjee
30 Sep 2017 Author responded Author comments - Jin Huang
Resubmission - Version 2
30 Sep 2017 Submitted Manuscript version 2
6 Oct 2017 Reviewed Reviewer Report - Aditi Chatterjee
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
4 Dec 2017 Editorially accepted
22 Dec 2017 Article published 10.1186/s12885-017-3875-3

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
(2)
Department of Dermatology, XiangYa Hospital, Central South University, Changsha, China
(3)
Department of Clinical Pharmacology, XiangYa Hospital, Central South University, Changsha, China
(4)
Hunan Key Laboratory of Pharmacogenetics, Changsha, China
(5)
Moffitt Cancer Center, DeBartolo Family Personalized Medicine Institute, Tampa, USA
(6)
Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
(7)
The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
(8)
Department of Hepatobiliary Surgery, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
(9)
Department of gastroenterology and urology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
(10)
Department of General Surgery, Xiangya Hospital of Central South University, Changsha, People’s Republic of China
(11)
Cancer Research Institute, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South University, Changsha, China

Advertisement